Zobrazeno 1 - 3
of 3
pro vyhledávání: '"R. N., Salas"'
Autor:
Sorensen, C., Lehmann, E., Holder, C., Hu, J., Krishnan, A., Münzel, T., M. B., Rice, R. N., Salas
Publikováno v:
BMJ: British Medical Journal; 10/15/2022, Vol. 379 Issue 8356, p114-116, 3p
Autor:
E.A. Klein, R. N. Salas, Paul Elson, Brian R. Lane, Robert Dreicer, Steven C. Campbell, Laura D. Wood, Jorge A. Garcia, Andrew J. Stephenson, B. I. Rini
Publikováno v:
Journal of Clinical Oncology. 27:5096-5096
5096 Background: Sunitinib inhibits VEGF and related receptors, with high tumor shrinkage rates in metastatic (met) RCC. Shrinkage of primary tumors has been observed, although prospective investigation is lacking. The ability of sunitinib to convert
Autor:
B. I. Rini, R. N. Salas, Ronald M. Bukowski, Jorge A. Garcia, Laura D. Wood, Paul Elson, Joanna Ireland, Jennifer S. Ko, James H. Finke
Publikováno v:
Journal of Clinical Oncology. 26:5099-5099
5099 Background: Sunitinib is an oral tyrosine kinase inhibitor of VEGFR-2, PDGFR, KIT, and FLT3 and a first line standard of care for mRCC. Temsirolimus, also approved for mRCC, is an analog of th...